AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase 3b study titled DESTINY-Breast15 to evaluate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) in patients with unresectable and/or metastatic HER2-low or HER2 IHC 0 breast cancer. The study aims to determine how long T-DXd can provide clinical benefits by measuring the time to next treatment (TTNT) in both hormone receptor-negative and positive patients.
The intervention being tested is Trastuzumab Deruxtecan, an anti-HER2-antibody drug conjugate administered intravenously. It is designed to target and treat specific types of breast cancer by delivering chemotherapy directly to cancer cells.
The study follows a non-randomized, parallel intervention model without masking, focusing on treatment as its primary purpose. It includes four experimental cohorts based on hormone receptor status and HER2 expression levels.
Key dates for the study include an actual start date of December 30, 2023, with the latest update submitted on July 28, 2025. These dates are crucial for tracking the study’s progress and anticipating future results.
The ongoing study could significantly impact AstraZeneca’s stock performance and investor sentiment, especially if the results demonstrate a substantial clinical benefit. This could position AstraZeneca favorably against competitors in the oncology market, enhancing its portfolio in targeted cancer therapies.
The study is currently recruiting, with further details available on the ClinicalTrials portal.